|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
|
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Current assets | ||||||||||
| Cash and cash equivalents | ||||||||||
| Marketable securities | ||||||||||
| Accounts receivable, net | ||||||||||
| Inventory | ||||||||||
| Prepaid expenses and other current assets | ||||||||||
| Total current assets | ||||||||||
| Property and equipment, net | ||||||||||
| Goodwill | ||||||||||
| Other assets | ||||||||||
| Total assets | ||||||||||
| Liabilities and Stockholders’ Equity | ||||||||||
| Current liabilities | ||||||||||
| Accounts payable | ||||||||||
| Accrued expenses and other current liabilities | ||||||||||
| Total current liabilities | ||||||||||
| Other liabilities | ||||||||||
| Total liabilities | ||||||||||
| Redeemable convertible preferred stock, $0.0001 par value; 0 and 91,131 shares authorized as of December 31, 2024 and 2023, respectively; 0 and 90,891 shares issued and outstanding as of December 31, 2024 and 2023, respectively; liquidation preference of $0 and $265,699 as of December 31, 2024 and 2023, respectively | ||||||||||
| Stockholders’ equity | ||||||||||
| Common stock, $0.0001 par value; 1,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 173,485 and 170,186 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | ||||||||||
| Additional paid-in capital | ||||||||||
| Accumulated other comprehensive (loss) income | ||||||||||
| Retained earnings | ||||||||||
| Total stockholders’ equity | ||||||||||
| Total liabilities and stockholders’ equity |
Loading...
